Última actualización 8 de julio de 2026
Key finding
Hazard ratio (95% CI) 0.84 (0.74–0.95)
The Finerenone Trial investigated the efficacy and safety of finerenone compared to placebo in patients with heart failure, demonstrating significant benefits.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
High Risk
Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.
Plain-language summary
A plain-language read of the study's main message and where it applies.
Study focus
The Finerenone Trial investigated the efficacy and safety of finerenone compared to placebo in patients with heart failure, demonstrating significant benefits.
These findings are clinically significant as they suggest that finerenone may provide an effective treatment option for patients with heart failure, potentially improving their quality of life and reducing hospitalizations, which are critical concerns in managing this condition.
Effectiveness of finerenone remains unclear due to unspecified evidence data. The study's population characteristics may limit generalizability. The trial did not include long-term follow-up data.
Published in
Publication details and source links for this paper.
Panagiotis IG, Christodoula K, Ioannis K, et al. Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure. American Journal of Cardiovascular Drugs. 2025;25(4):427-432. doi:10.1007/s40256-025-00723-2
Finerenone was superior to placebo in improving the primary composite outcome of worsening heart failure events.
Finerenone showed a significant reduction in hospitalization for heart failure compared to placebo.
Finerenone improved outcomes related to death from cardiovascular causes compared to placebo.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Finerenone (nonsteroidal mineralocorticoid receptor antagonist) and Cardiovascular death, Hospitalization for heart failure, Total worsening heart failure events and death from cardiovascular causes.
This study contributes evidence to
Primary intervention
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
3
Evidence pairs
39
Related studies
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
matched_outcome
Core evidence
The primary outcomes reported in this study.
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Cardiovascular death
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Cardiovascular death
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Hospitalization for heart failure
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Hospitalization for heart failure
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Total worsening heart failure events and death from cardiovascular causes
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Total worsening heart failure events and death from cardiovascular causes
Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Finerenone (nonsteroidal mineralocorticoid receptor antagonist) and Cardiovascular Outcomes, Finerenone (nonsteroidal mineralocorticoid receptor antagonist) and Cardiovascular death.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Cardiovascular Outcomes
Measures Cardiovascular Outcomes as a key outcome.
All studies on Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Contributes to Finerenone (nonsteroidal mineralocorticoid receptor antagonist) evidence base.
All studies measuring Cardiovascular death
Measures Cardiovascular death as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in the evidence archive.
2 results
1 results
2 results
2 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) appears to improve Hospitalization for heart failure.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Hospitalization for heart failure
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) appears to improve Cardiovascular death.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Cardiovascular death
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) appears to improve Total worsening heart failure events and death from cardiovascular causes.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Total worsening heart failure events and death from cardiovascular causes
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, archive views, and research summaries.
Open broader archive views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.